【摘要】 目的探讨英夫利昔单抗治疗强直性脊柱炎对尿酸的影响。方法对2008年8月1日—2015年10月31日深圳市中医院确诊强直性脊柱炎住院病例进行回顾性统计分析,对比英夫利昔单抗治疗前后尿酸等数据进行统计分析。结果治疗前后患者的血沉、C-反应蛋白、尿酸变化对比,差异具有统计学意义(P<0.05);治疗前,高尿酸血症7例,高尿酸患病率22.58%;治疗后,高尿酸血症10例,高尿酸患病率38.71%。结论英夫利昔单抗治疗强直性脊柱炎患者可能影响尿酸水平导致其升高。更多还原

【Abstract】 Objective To explore the effect of Infliximab in treatment of ankylosing spondylitis(AS) of uric acid. Methods A total of 31 cases of patients with AS received and cured in Shenzhen Chinese Traditional Medical Hospital during the period from 1 August 2008 to 31 October 2015 were selected as research objects, given before and after treatment with Infliximab for statistical analysis. Results ESR, CRP, Metabolic parameters: uric acid, triglyceride, total cholesterol, blood glucose. Clinical signs: the activity of the thorax, the distance between the pillow and the wall, the distance of the finger, the modified of the Schober test, the difference is statistically significant(P<0.05), treatment of 7 cases of hyperuricemia and hyperuricemia prevalence rate 22.58%. After the treatment, there were 10 cases with hyperuricemia and hyperuricemia prevalence rate of 38.71%. Conclusion Infliximab treatment of ankylosing spondylitis patients elevated levels of uric acid influence更多还原